Literature DB >> 3598625

Central nervous system (CNS) penetration of homoharringtonine (HHT).

N Savaraj, L G Feun, K Lu, M Leavens, R Moser, W S Fields, T L Loo.   

Abstract

Generally tritiated homoharringtonine ([3H]HHT, 150 microCi, 430 micrograms) was administered intravenously to seven patients at varying times before surgical resection of malignant brain tumor. Plasma, urine, cerebrospinal fluid (CSF), and tumor specimens were obtained during surgery, and the concentrations of HHT, its major metabolite, and [3H]HHT equivalent were determined chromatographically and radiochemically. For [3H]HHT equivalent, the concentration in tumor ranged from 0.6 to 4.3 ng/g and the ratio of tumor to plasma concentration from 0.5 to 1.8. In one patient who had CSF available for drug determination, the CSF to plasma ratio of total [3H]HHT was 0.3 at 45 minutes after drug administration and less than 0.2 ng/ml was unchanged HHT. For unchanged HHT, drug concentration in tumor ranged from undetectable (4 patients) to 1.8 ng/g. A major metabolite of HHT was detectable in the tumor specimens of all the patients. These results indicate that homoharringtonine can penetrate into brain tumors; in 3 patients with brain tumors, the ratios of HHT concentration in the tumor to that in the concurrent plasma were greater than one.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3598625     DOI: 10.1007/bf00162769

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  2 in total

1.  Inhibition of protein synthesis in intact HeLa cells.

Authors:  J S Tscherne; S Pestka
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

2.  Phase I clinical investigation of homoharringtonine.

Authors:  S S Legha; M Keating; S Picket; J A Ajani; M Ewer; G P Bodey
Journal:  Cancer Treat Rep       Date:  1984-09
  2 in total
  6 in total

1.  Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors.

Authors:  L G Feun; N Savaraj; H Landy; H Levin; T Lampidis
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

Review 2.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.

Authors:  John Nemunaitis; Alain Mita; Joe Stephenson; Monica M Mita; John Sarantopoulos; Swami Padmanabhan-Iyer; Nisha Nanda; Lyon Gleich; Annie-Claude Benichou; Adam Craig
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-04       Impact factor: 3.333

5.  Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.

Authors:  Philip Dao Trong; Gerhard Jungwirth; Tao Yu; Stefan Pusch; Andreas Unterberg; Christel Herold-Mende; Rolf Warta
Journal:  Cells       Date:  2020-06-03       Impact factor: 6.600

6.  High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinoma.

Authors:  Nicholas C Wolff; Andrea Pavía-Jiménez; Vanina T Tcheuyap; Shane Alexander; Mridula Vishwanath; Alana Christie; Xian-Jin Xie; Noelle S Williams; Payal Kapur; Bruce Posner; Renée M McKay; James Brugarolas
Journal:  Oncotarget       Date:  2015-07-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.